BidaskClub lowered shares of Ascendis Pharma A/S (NASDAQ:ASND) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

ASND has been the topic of several other research reports. Stifel Nicolaus cut their target price on Ascendis Pharma A/S from $85.00 to $81.00 and set a buy rating on the stock in a research note on Thursday, August 30th. Wedbush set a $79.00 target price on Ascendis Pharma A/S and gave the company a buy rating in a research note on Thursday, August 30th. ValuEngine raised Ascendis Pharma A/S from a buy rating to a strong-buy rating in a research note on Thursday, August 2nd. Wells Fargo & Co lifted their target price on Ascendis Pharma A/S from $83.00 to $88.00 and gave the company an outperform rating in a research note on Thursday, August 30th. Finally, Canaccord Genuity began coverage on Ascendis Pharma A/S in a research note on Tuesday, August 7th. They set a buy rating and a $81.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. Ascendis Pharma A/S currently has a consensus rating of Buy and a consensus price target of $77.25.

Shares of Ascendis Pharma A/S stock opened at $59.84 on Tuesday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -13.82 and a beta of 0.68. Ascendis Pharma A/S has a 1-year low of $31.56 and a 1-year high of $76.99.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, August 29th. The biotechnology company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.03) by $0.37. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 49.69% and a negative net margin of 17,641.85%. On average, equities research analysts expect that Ascendis Pharma A/S will post -4.22 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Orbimed Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 31.1% in the 2nd quarter. Orbimed Advisors LLC now owns 4,413,291 shares of the biotechnology company’s stock worth $293,572,000 after buying an additional 1,045,976 shares in the last quarter. Sofinnova Ventures Inc bought a new stake in shares of Ascendis Pharma A/S in the 1st quarter worth $162,160,000. venBio Select Advisor LLC raised its stake in shares of Ascendis Pharma A/S by 22.7% in the 1st quarter. venBio Select Advisor LLC now owns 2,063,336 shares of the biotechnology company’s stock worth $134,942,000 after buying an additional 382,312 shares in the last quarter. Millennium Management LLC raised its stake in shares of Ascendis Pharma A/S by 25.4% in the 1st quarter. Millennium Management LLC now owns 665,727 shares of the biotechnology company’s stock worth $43,539,000 after buying an additional 134,936 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of Ascendis Pharma A/S by 8.1% in the 2nd quarter. BlackRock Inc. now owns 438,789 shares of the biotechnology company’s stock worth $29,188,000 after buying an additional 32,980 shares in the last quarter. 94.56% of the stock is currently owned by institutional investors.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Article: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.